Agenda & Faculty, April 19-20, 2024

Day 1 Moderated by: Prithviraj Bose

07:30

Registration Opens

08:50

Opening Introduction to the meeting – Ryan Fitzpatrick, CEO, MD Education

Session I

09:00

Jason Gotlib

Update on Systemic Mastocytosis

Jason Gotlib, MD - Stanford University School of Medicine, California

09:20

Jason Gotlib

Workup and Management of Eosinophilia in 2024

Jason Gotlib, MD - Stanford University School of Medicine, California

09:40

Andrew Kuykendall

Of Rux, Ropeg and Rusfertide – Treatment of PV comes of age

Andrew Kuykendall, MD - Moffit Cancer Center, Texas

10:00

Panel Discussion

10:30

Coffee Break

Session II

10:50

abdulraheem-yacoub

What’s happening in ET in 2024

Abdulraheem Yacoub, MD - University of Kansas, Kansas

11:10

Lucia

Current status of interferons in MPNs

Lucia Masarova, MD - MD Anderson Cancer Center, Texas

11:30

Lucia (2)

Early/pre-fibrotic PMF – Diagnosis, Prognosis and Management

Pankit Vachhani, MD - The University of Alabama, Alabama

11:50

Panel Discussion

12:20

Independent Expert Discussion supported by GSK

13:05

Lunch Break

Session III

13:55

Nikolai-Podolstev

Making sense of all the prognostic models for MF

Nikolai Podoltsev, MD - Yale School of Medicine, Connecticut

14:15

Ruben

JAK inhibitors for MF – where we stand in 2024

Ruben Mesa, MD - Levine Cancer Institute, Charlotte, North Carolina

14:35

Stephen_Oh

Management of Anemia in Myelofibrosis – Old and New Drugs

Stephen  T. Oh, MD - Washington University, Missouri

14:55

Panel Discussion

15:15

Room refresh and exhibit viewing

Session IV

15:35

Novel mechanisms of drug action in MF

Prithviraj Bose, MD - MD Anderson Cancer Center, Houston, Texas

15:55

Jeanne

Allogeneic Stem Cell Transplantation for MF

Jeanne Palmer, MD - Mayo Clinic, Arizona

16:15

Naveen Pemmaraju

Moving Beyond Spleen and Symptoms: Time for New Endpoints in MF?

Naveen Pemmaraju, MD - MD Anderson Cancer Center, Houston, Texas

16:35

Panel Discussion

16:55

Adjourn

08:00 Registration Opens

Day 2 Moderated by: Rami Komrokji, MD

Session V:

09:00

Mrinal Patnaik

“Pre MDS” CHIP and CCUS

Mrinal Patnaik, MD - Mayo Clinic, Arizona

09:20

Sanam

Updates on MDS diagnosis and classification

Sanam Loghavi, MD - MD Anderson Cancer Center, Texas

09:40

Naval Daver

Update on clinical trials in HR-MDS

Naval Daver, MD - MD Anderson Cancer Center, Texas

10:00

Panel Discussion

10:20

Coffee Break

Session VI

Debate 1: Moderated by: Rami Komrokji, MD
Luspatercept is the new standard of care as first line therapy for LR-MDS

10:40

Yazan_Madanat

Yes

Yazan Madanat, MD - UT Southwestern Medical Center, Dallas, Texas

10:50

No

Maximilian Stahl, MD - Dana-Farber Cancer Institute, Boston, Massachusetts

11:00

Debate Discussion

11:10

Measuring the clinical benefit of therapies in Lower and higher risk MDS

Amer Zeidan, MD - Northwestern University Feinberg School of Medicine, Illinois

11:30

Michael_Savona

When and how to use Imetelstat for LR-MDS

Michael R. Savona, MD - Vanderbilt University Medical Center, Nashville, Tennessee

11:50

Panel Discussion

12:10

Industry supported independent expert discussion

12:55

Lunch Break & Group Photo

Session VII: Moderators: Rami Komrokji

13:45

Rami

Controversies in managing del 5q: early treatment and impact of other somatic mutations

Rami Komrokji, MD - MD Anderson Cancer Center, Texas

14:05

Uma

Treatment of Higher risk MDS patients not eligible for allogeneic stem cell transplant

Uma Borate, MD The Ohio State University, Ohio

14:25

Rafael Bejar

How do I risk stratify MDS patients?

Rafael Bejar, MD - University of California, San Diego, California

14:45

Panel discussion

15:05

Independent expert discussion supported by Abbvie

15:50

Coffee Break

Session VIII

Fellows / Junior Debate 1: Moderated by: TBD
Treatment is needed prior to Allo-SCT

16:00

Luis_Aguirre

Yes

Luis Aguirre, MD - Dana-Farber Cancer Institute, Boston, Massachusetts

16:10

Somedeb Ball

No

Somedeb Ball, MD - Vanderbilt University Medical Center, Nashville, Tennessee

16:20

Debate Discussion

16:40

David

How do I manage TP53 MDS?

David Sallman, MD - Moffit Cancer Center, Texas

17:00

Beyond allogeneic stem cell transplant in MDS: Immune therapies and CAR-T

Hany Elmariah, MD - Moffit Cancer Center, Florida

17:20

MDS/MPD

Guillermo Montalban Bravo, MD - MD Anderson Cancer Center, Houston, Texas

17:40

Panel discussion

18:00

Adjourn

It is our pleasure to invite you to participate in this one-of-a-kind event.

If you need additional information please contact us at:

office@md-education.com

MD Education Ltd
4/4a Bloomsbury Square,
London, WC1A 2RP

MD Education USA LLC
4600 140th Avenue North, Suite 180,
Clearwater, Florida 33762

Mary Frances Mc Mullin, MD

Queen’s University Belfast, Ireland

Professor Mary Frances McMullin   trained in Haematology in N. Ireland and The Royal Postgraduate Medical School, Hammersmith hospital, London. She was appointed senior lecturer in haematology in QUB in 1991 and consultant haematologist and   proceeded to Professor of Haematology in 2006. Her clinical and research interests include myeloproliferative neoplasms, investigation of the rare congenital erythrocytosis, and acute myeloid leukaemia. She now has over 250 peer reviewed publications in the area.

Paola Guglielmelli, MD

Univerisity of Florence, Italy

Paola Guglielmelli, MD, PhD
CRIMM- Center of Research and Innovation for MPN- Azienda Ospedaliera
Universitaria Careggi. University of Florence, Italy

I graduated in Medicine at the University of Florence in 2003. I got my Specialty Degree in Hematology in 2007. In 2010 Post-doctoral degree at the School in Clinical and Experimental Oncology at the University of Florence. In 2018 Associate Professor in Hematology, and from 2021: Director, Centre for Research and Innovation of Myeloproliferative Neoplasms (CRIMM), AOU Careggi-Florence.
My main scientific interests concern experimental and clinical issues of myeloproliferative disorders.
I have been working on the molecular characterization in hematopoietic progenitors of patients with MPNs and I have more recently developed novel integrated clinical-molecular prognostic models in MPN patisnts. I have been also involved in the study of a novel animal model of myelofibrosis.
Current areas of research include preclinical studies on JAK-STAT pathway, PI3K/Akt/mTOR pathway and calreticulin as a therapeutic target in myeloproliferative neoplasms, coding and not- coding RNA expression profile, exome and RNA sequencing. Furthermore, I am strongly committed to clinical work, having in routine charge patients with MPNs and being involved in clinical protocols with novel drugs and in epidemiologic studies. Since 2015, I ‘m contributing to the development of advanced molecular methodologies for the research and quantification of the most common mutations in MPN, mastocytosis, eosinophilias and mutational anomalies associated with erythrocytosis, platelet or familial platelet disorders. From 18/5/2020 the laboratory has carried out first and second level molecular tests for acute myeloid leukemia. Author of 261 publications on international scientific journals (ISI h-index=63 and proceedings of national and international conferences.

Ruben Mesa, MD,

Wake Forest University in Winston-Salem, USA

Ruben Mesa, MD, FACP recently began his tenure leading the mission and programs against cancer across Atrium Health and Atrium Health Wake Forest Baptist with the joint roles of President, Enterprise Cancer Service Line Atrium Health; Enterprise Senior Vice President for Atrium Health; Executive Director of the NCI Comprehensive Cancer based at Wake Forest Baptist; and Vice Dean for cancer programs at Wake Forest School of Medicine. In these roles Dr. Mesa oversees all efforts related to cancer practice, research and education across Atrium Health as a system including Wake Forest Baptist, Levine Cancer Institute, and all regional sites.
Dr. Mesa previously was the Executive Director of the NCI Designated Mays Cancer Center at UT Health San Antonio MD Anderson from 2017-2023 where he developed and grew the cancer service line, co-led the development and construction of a new cancer focused hospital, grew cancer faculty, peer reviewed funded research and successful renewed the NCI designation in 2020. Earlier in his career Dr Mesa practiced hematology at Mayo Clinic (MN 2002-2009, and Arizona (2009-2017)) where he was Chair of Hematology & Medical Oncology and Deputy Director of the Mayo Clinic Comprehensive Cancer Center.

Luca Malcovati, MD

IRCCS S. Matteo Hospital Foundation & University of Pavia, Italy

Dr. Lucia Messingerova has been working in the field of research on resistance to
hemato-oncological treatment since 2010, when during her PhD. studies she focused on the function of ABC transporters in the reduction of cytotoxic effect of different substances on leukemic cell lines. During her doctoral studies, she got a fellowship at the prestigious Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins Hospital, USA. After completing her studies, she started to work at the Slovak University of Technology, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents used to treat patients with myelodysplastic syndromes and acute myeloid leukemia. Currently, she also works as an alternanting representative of Slovakia in Sub-Group on Cancer under the Steering Group on Health Promotion, Disease Prevention and Management of Non- Communicable Diseases.

Lucia Messingerova, MD

Slovak Academy of Sciences, Slovakia

Dr. Lucia Messingerova has been working in the field of research on resistance to
hemato-oncological treatment since 2010, when during her PhD. studies she focused on the function of ABC transporters in the reduction of cytotoxic effect of different substances on leukemic cell lines. During her doctoral studies, she got a fellowship at the prestigious Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins Hospital, USA. After completing her studies, she started to work at the Slovak University of Technology, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents used to treat patients with myelodysplastic syndromes and acute myeloid leukemia. Currently, she also works as an alternanting representative of Slovakia in Sub-Group on Cancer under the Steering Group on Health Promotion, Disease Prevention and Management of Non- Communicable Diseases.